THC-HSΔ9-THC hemisuccinate
Prodrug ester of Δ9-THC, studied as a suppository to avoid hepatic first pass; never authorised.
C₂₅H₃₄O₅
CAS 52855-15-9
- Family
- Semi-synthetic cannabinoidEster or prodrug
- Molar mass
- 414.54 g/mol
Updated on
In plain terms
THC hemisuccinate is a THC modified to be given as a suppository, so that a large part of the THC is not destroyed by the liver as when it is swallowed. In a 2018 study, this form delivered 2.44 times more THC into the blood than a capsule of the same dose. It has never been authorised as a medicine.
Receptors and activity
Pharmacology
Δ9-THC hemisuccinate is a prodrug ester of tetrahydrocannabinol studied for rectal administration, to get around the low and variable oral bioavailability of THC caused by gut metabolism and hepatic first pass (Mattes et al. 1993). Among several polar esters tested as suppositories in monkeys, only the hemisuccinate delivered Δ9-THC in a lipophilic base; its bioavailability was estimated at 13.5%, with a mean residence time of 5.8 hours against 3 hours intravenously (ElSohly et al. 1991). In dogs, it reached 67%. In three adult women, a suppository of 11.8 mg of ester (9 mg of THC) gave an area under the curve more than 30 times that of the oral form. In the 2018 study in male volunteers, Δ9-THC exposure after a 10 mg-equivalent suppository was 2.44 times that of a 10 mg dronabinol capsule. No marketing authorisation was found.
Key sources.
- ElSohly MA, Stanford DF, Harland EC et al. Rectal bioavailability of Δ9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 1991;80:942-5 (new tab)PMID 1664466
- ElSohly MA, Little TL Jr, Hikal A et al. Rectal bioavailability of Δ9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav 1991;40:497-502 (new tab)PMID 1666913
- Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993;44:745-7 (new tab)PMID 8383856
- Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y. The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996;34:446-52 (new tab)PMID 8897084
- ElSohly MA, Gul W, Walker LA. Pharmacokinetics and tolerability of Δ9-THC-hemisuccinate in a suppository formulation as an alternative to capsules for the systemic delivery of Δ9-THC. Med Cannabis Cannabinoids 2018;1:44-53 (new tab)PMID 34676321
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
History
- Source
- Absent from cannabis: it is an ester of Δ9-THC whose phenol function is esterified by succinic acid, the second acid function remaining free. It was designed as a prodrug for the rectal administration of Δ9-THC; no marketing authorisation was found.
Route of preparation
Chemical process
No plant pathway. It is a semi-synthetic monoester of Δ9-THC (hemisuccinate at position 1), described here by chemical class only.
Legal framework
- European Union
Not named in the UN conventions: Schedule II of the 1971 Convention covers Δ9-THC (dronabinol), its stereochemical variants and its salts, with no clause on esters. No European Union measure of its own and no marketing authorisation were found. Checked 20/10/2026.
- France
Narcotic: the entry "Tetrahydrocannabinols, their esters, ethers, salts as well as the salts of the aforementioned derivatives" of the decree of 22 February 1990 names THC esters explicitly; it was moved from annex IV to annex III by the ANSM decision of 6 February 2026. The hemisuccinate also meets the generic class of benzo[c]chromene derivatives, which allows at position 1 a hydroxyl function "esterified or not" (annex IV, ANSM decisions of 22 May and 3 June 2024). Checked 20/10/2026.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Semi-synthetic cannabinoid › Ester or prodrug
- Chemistry
C5 side chain · neutral form
- Verification
Every fact on this entry was checked against its primary sources on 20 October 2026.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- ElSohly MA, Stanford DF, Harland EC et al. Rectal bioavailability of Δ9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 1991;80:942-5 (new tab)PMID 1664466
- ElSohly MA, Little TL Jr, Hikal A et al. Rectal bioavailability of Δ9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav 1991;40:497-502 (new tab)PMID 1666913
- Mattes RD, Shaw LM, Edling-Owens J, Engelman K, ElSohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993;44:745-7 (new tab)PMID 8383856
- Brenneisen R, Egli A, ElSohly MA, Henn V, Spiess Y. The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996;34:446-52 (new tab)PMID 8897084
- ElSohly MA, Gul W, Walker LA. Pharmacokinetics and tolerability of Δ9-THC-hemisuccinate in a suppository formulation as an alternative to capsules for the systemic delivery of Δ9-THC. Med Cannabis Cannabinoids 2018;1:44-53 (new tab)PMID 34676321
- ANSM, decision of 6 February 2026 amending the list of substances classified as narcotics and the list of psychotropic substances (tetrahydrocannabinols in annex III) (new tab)
- ANSM, decision of 22 May 2024 amending the list of substances classified as narcotics (generic benzo[c]chromene class), supplemented by the decision of 3 June 2024 (new tab)
- ANSM, consolidated list of substances classified as narcotics, updated 26/06/2026 (new tab)
Identifiers
Names
- Common name
- Δ9-THC hemisuccinate
- IUPAC name
- 4-[[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl]oxy]-4-oxobutanoic acid
- Other names
- THC hemisuccinate · THC-HS · Δ9-THC-hemisuccinate · dronabinol hemisuccinate
Identifiers
- Formula
- C₂₅H₃₄O₅
- CAS
- 52855-15-9
- PubChem CID
- 162707(new tab)
- InChIKey
- YVOODUUYDJKFDY-RTBURBONSA-N
- SMILES
- CCCCCC1=
CC2= C([C@@H] 3C= C(CC[C@H] 3C(O2) (C) C) C) C(= C1) OC(= O) CCC(= O) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.